Holen Sie sich die Stockscreener-App
25.54
0.95%
0.24
Schlusskurs vom Vortag:
$25.30
Offen:
$25.33
24-Stunden-Volumen:
1.72M
Relative Volume:
1.08
Marktkapitalisierung:
$1.73B
Einnahmen:
$2.76B
Nettoeinkommen (Verlust:
$-358.70M
KGV:
-5.1388
EPS:
-4.97
Netto-Cashflow:
$-35.90M
1W Leistung:
-8.62%
1M Leistung:
-8.88%
6M Leistung:
-42.58%
1J Leistung:
-27.81%
1-Tages-Spanne:
$25.32
$26.67
1-Wochen-Bereich:
$25.25
$28.12
52-Wochen-Spanne:
$23.77
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Vergleichen Sie QDEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
25.54 | 1.89B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
What drives QuidelOrtho Corporation stock priceHigh-velocity capital appreciation - jammulinksnews.com
What analysts say about QuidelOrtho Corporation stockOverwhelming profit margins - Autocar Professional
QuidelOrtho to Report Second Quarter 2025 Financial Results - Stock Titan
Is QuidelOrtho Corporation a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
QuidelOrtho Corporation Stock Analysis and ForecastExceptional market positioning - jammulinksnews.com
QuidelOrtho and BÜHLMANN launch FCAL turbo and FPELA turbo assays on VITROS Systems - SelectScience
RBC Capital Maintains a Buy Rating on QuidelOrtho Corporation (QDEL), Sets a $60 PT - MSN
QuidelOrtho, Acadia Healthcare, Elevance Health, Molina Healthcare, and Alignment Healthcare Stocks Trade Down, What You Need To Know - MSN
Real Labs, Actual Decisions With Actionable Six Sigma Metrics - The Malaysian Reserve
QuidelOrtho Announces Featured ADLM Session on Six Sigma Insights for Lab Performance - AInvest
QuidelOrtho to present at ADLM on Six Sigma lab performance improvement. - AInvest
Six Sigma Lab Excellence: Top Medical Experts Share Game-Changing Performance Metrics at ADLM Conference - Stock Titan
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
Investors in QuidelOrtho (NASDAQ:QDEL) from five years ago are still down 88%, even after 3.8% gain this past week - simplywall.st
QuidelOrtho Corporation and Buildman Laboratories AG Announces Availability of the BuHLMANN FCAL Turbidimetric Immunoassays on Vitroal Pancreatic Elastase - MarketScreener
QuidelOrtho and Bühmann Laboratories AG announce availability of Fecal Calprotectin (Fcal®) Turbo and Fecal Pancreatic Elastase (Fpela®) Turbo assays on Vitros systems as a Microtip partnership assay (Mpa) - MarketScreener
QuidelOrtho's New 10-Minute Diagnostic Tests Transform IBD and Pancreatic Disease Detection - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
A Look Back at Medical Devices & SuppliesImaging, Diagnostics Stocks’ Q1 Earnings: QuidelOrtho (NASDAQ:QDEL) Vs The Rest Of The Pack | FinancialContent - FinancialContent
User - FinancialContent
Best Value Stocks to Buy for July 8th - The Globe and Mail
QuidelOrtho announces key leadership changes - Medical Buyer
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs | QDEL Stock News - GuruFocus
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs - PR Newswire
5 Revealing Analyst Questions From QuidelOrtho’s Q1 Earnings Call - Yahoo Finance
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock - Nasdaq
RBC Capital Keeps Their Buy Rating on QuidelOrtho (QDEL) - The Globe and Mail
QuidelOrtho's Russell 1000 Exit: Opportunity in the Shadows of Index Exclusion - AInvest
QuidelOrtho Corporation(NasdaqGS: QDEL) added to Russell 3000 Growth Index - MarketScreener
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Yahoo Finance
QuidelOrtho Nabs LEX in $100M M&A - San Diego Business Journal
What Makes QuidelOrtho (QDEL) a New Buy Stock - Nasdaq
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):